IPOX® 100 U.S. hits fresh all-time High Monday as top IPO M&A picks soars / ETF in focus: FPX
IPOX® Schuster LLC, the firm behind the IPOX® Strategies, is pleased to note a fresh all-time High in its IPOX® 100 U.S.
As of 10 am ET, the broad-based portfolio added to +0.49% to +4.82% YTD, far outpacing the declining benchmarks, including the Nasdaq 100 (NDX) and S&P 500 (SPX).
“After adding +48.22% during 2020, the IPOX® 100 U.S. continues to be driven by strong Momentum in a diversified mix of portfolio holdings resilient to COVID-19 inflicted global economic uncertainties and the potential for uniquely positive outcomes”, said J. Schuster, manager of the IPOX® Strategies.
Today’s strength is driven by significant gains recorded by the IPO M&A portion of the portfolio, including drug maker IPOX heavyweight Eli Lilly (LLY US: +10.43%, on promising Alzheimer treatment news) and Life Sciences company Exact Sciences (EXAS US: +13.38%, on positive earnings).
The IPOX® 100 U.S. serves as the underlying for the USD billion 2.1 IPOX 100 U.S. ETF (ticker: FPX) (ETF factsheet: https://bit.ly/39lIhOM).
For IPOX® 100 U.S. factor research, please see https://bit.ly/35uyu6d
For further information, including licensing, mandate coverage and research, please contact us using the co-ordinates below.
The IPOX Team
IPOX Schuster LLC
225 West Washington, Suite 1675
Chicago, IL 60606
1-312-339-4114 (24.7 support)